Intended For US Audiences Only.

You are leaving this site!

By clicking YES, you will be directed to another website. Click NO to remain on this page. Do you wish to continue to another website?

PRIVACY STATEMENT

When you browse the BIVIGAM Website your personal information is not revealed to us. Details such as your name and e-mail address remain anonymous. As usual with virtually all web pages, the only initial information recorded is your IP address, which helps us to administer our Website and identify broad demographic information, such as your browser type and geographic location.

ADMA Biologics collects personally identifiable information, such as names, addresses, e-mail addresses and the like, only when voluntarily provided by a Website user. ADMA Biologics does not want to receive confidential, proprietary or personal medical information through Website communications.

Any communication with the BIVIGAM Website or any other e-mail transmission to ADMA Biologics on this Website is non-confidential. ADMA Biologics has no obligation to refrain from reproducing, publishing or otherwise using third-party information for any purpose, and ADMA Biologics may use the content of any such communication, including any ideas or know how disclosed therein for ADMA Biologics’ own commercial purposes. Whoever transmits any communication to this Website or otherwise to ADMA Biologics is solely responsible for its accuracy and completeness. This site is intended to provide a service to users.

All rights not expressly granted herein are reserved to ADMA Biologics.

Indication

BIVIGAM is an Immune Globulin Intravenous (Human), 10% Liquid, indicated for the treatment of patients with primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

Important Safety Information for BIVIGAM®

WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE

  • Thrombosis may occur with immune globulin intravenous (IGIV) products, including BIVIGAM. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, a history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Use of immunoglobulin intravenous (IVIG) products, particularly those containing sucrose, has been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Patients at risk of acute renal failure include those with any degree of preexisting renal insufficiency, diabetes mellitus, advanced age (above 65 years of age), volume depletion, sepsis, paraproteinemia, or receiving known nephrotoxic drugs.
  • Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. BIVIGAM does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or renal failure, administer BIVIGAM at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Tap for important safety information for BIVIGAM